Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-comparator-controlled, parallel-group, phase 2 trial
Rosenstock J, Frias J, Jastreboff AM et al.
The Lancet, 2023
DOI: 10.1016/S0140-6736(23)01053-X